Deciduous Therapeutics
Senescent cells, which are characterized by irreversible damage and an inflammatory secretome, are considered a key driving force behind many age-related diseases. Due to a failure in immune surveillance, senescent cells accumulate and impact their local environment by inducing inflammation and promoting extracellular matrix remodeling, thus resulting in a myriad of metabolic and fibrotic consequences. Therefore, enabling the removal of senescent cells dramatically ameliorates disease pathologies in many age-related diseases, leading to overall improvements in health-span. At Deciduous Therapeutics, we have discovered novel molecules that can activate a critical endogenous immune surveillance mechanism to selectively remove senescent cells and thereby treat several classes of age-related diseases.
7-day free trial · no credit card
Verified contacts
7
available on Kipplo
LinkedIn employees
13
11 to 50 range
Open roles
—
no listings
Distinct roles
3
indexed titles
Tech stack
1
tools in use
Monthly traffic
309
organic / mo
Sign up free to see all 7 verified contacts at Deciduous Therapeutics
Free for 7 days · 50 credits · no card · only pay for verified records.
Decision-makers and verified team members
7 contacts with verified email or phone · masked until revealed.
- AR
Aaron Rapaport
Principal Scientist · Science
EmailPhone - MA
Mamoon Ali
Senior Research Associate · Research & Development
EmailPhone - SA
Scott Armstrong
Vice President of Research · Research & Development
EmailPhone
Showing 3 of 7 verified contacts
Top roles at Deciduous Therapeutics
3 distinct titles indexed · top 3 shown.
- 1principal scientist
- 1senior research associate
- 1vice president of research
Sign up to unlock all 7 contacts at Deciduous Therapeutics
Free for 7 days · 50 credits · no card · only pay for verified records.
Sign up to reveal 7 verified contacts at Deciduous Therapeutics
7-day trial · no credit card · cancel anytime · only pay for verified records.
Trusted by sales, marketing, and GTM engineering teams.